A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Trial Profile

A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Alpelisib (Primary) ; Elgemtumab (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 24 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 07 Jan 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top